The Université de Montréal team's identification of ATP5I as a direct metformin target in cell models represents a mechanistic advance beyond prior AMPK-centric models, yet the eLife study (Lefrançois et al., 2026) relies exclusively on in vitro knockouts without animal or human validation, limiting immediate translational weight. This work reveals how metformin perturbs ATP synthase assembly rather than catalysis alone, potentially explaining pleiotropic effects on energy metabolism that observational epidemiology has linked to reduced cancer incidence and extended lifespan. What the MedicalXpress coverage overlooks is the risk that ATP5I loss could confer metformin resistance in tumors, a pattern seen in prior mitochondrial-targeting agents. Synthesizing this with the TAME trial framework (Barzilai et al., Aging Cell 2016, n=~3,000 planned, observational-to-RCT transition) and a 2023 meta-analysis of 1.2 million patients showing 15-20% cancer risk reduction (Heckman-Stoddard et al., JNCI), the discovery points to ATP5I as a node integrating diabetes, senescence, and oncogenesis. No conflicts of interest were declared in the primary paper, but larger sample sizes in human mitochondrial proteomics are needed to confirm assembly effects. This cross-disease mapping elevates ATP5I from obscure subunit to high-value therapeutic lever.